Mocetinostat (MGCD0103) , ≥98% , 726169-73-9
| Pack Size | Price | Stock | Quantity |
| 5MG | RMB494.40 | In Stock |
|
| 25MG | RMB1039.20 | In Stock |
|
| 50MG | RMB1919.20 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Melting point: | >170oC (dec.) |
| Density | 1.340±0.06 g/cm3(Predicted) |
| storage temp. | RT |
| solubility | Soluble in DMSO (up to 25 mg/ml) |
| pka | 13.13±0.70(Predicted) |
| form | solid |
| color | Off-white |
| Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 2 months. |
Description and Uses
Mocetinostat (726169-73-9) is a class I, isoform-selective HDAC inhibitor, IC50s=0.15, 0.29, 1.66 and 0.59 μM for HDAC1, 2, 3 and 11 respectively.1 Induces hyperacetylation of histones, induces expression of the tumor suppressor p21WAF1 and inhibits proliferation of human cancer cells.2 Mocetinostat displays antifibrotic effects in ischemic heart failure.3 Attenuates the development of hypersensitivity in models of neuropathic pain.4 Active in vivo.5
Mocetinostat is a multi-targeted histone deacetylase inhibitor used in cancer therapy. Mocetinostat is undergoing clinical trials for the treatment of various cancers including follicular lymphoma, Hodgkin’s lymphoma and acute myelogenous leukemia.
